• Clearmind received a positive recommendation from an independent Data and Safety Monitoring Board to continue its FDA-approved Phase I/IIa trial of CMND-100 in patients with moderate to severe Alcohol Use Disorder.
• Top-line safety results have already been presented internally to the board, showing CMND-100 was well tolerated with no serious adverse events reported.
• Clearmind will advance to fourth cohort, raising tested dose to 160 mg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-043826), on April 15, 2026, and is solely responsible for the information contained therein.